文献速递胃肠外科围术期管理与 ERAS

代偿性肝硬化对代谢与减重手术全国趋势及结局的影响

National trend and impact of compensated cirrhosis in patients who underwent metabolic and bariatric surgery: a Nationwide Readmissions Database study.
PubMed 文献 · Surg Endosc · 2026-01-09

基于美国全国再入院数据库2016-2020年数据,纳入3064例肝硬化与538329例无肝硬化代谢与减重手术患者,肝硬化趋势无显著变化;肝硬化未增加院内死亡、90天再入院或多数主要并发症,但肝性脑病和急性心衰发生率更高,住院更长、费用更高、非居家出院更多;在肝硬化患者中,Roux-en-Y胃旁路术和十二指肠转位术较袖状胃切除术再入院率更高。

要点

  • 代偿性肝硬化患者行代谢与减重手术未增加院内死亡、90天再入院或多数主要并发症。
  • 肝硬化患者肝性脑病和急性心衰发生率更高,住院更长、费用更高、非居家出院更多。
  • 肝硬化患者中Roux-en-Y胃旁路术和十二指肠转位术较袖状胃切除术再入院率更高。

核心结论

  • 代偿性肝硬化合并肥胖患者行代谢与减重手术可能是安全的。

研究设计与样本

  • 回顾性队列研究,使用全国再入院数据库2016-2020年数据,肝硬化组3064例,非肝硬化组538329例。

主要发现

  • 肝硬化组与非肝硬化组院内死亡率分别为<11例(<0.36%)与99例(0.02%),差异无统计学意义(p=0.140)。
  • 90天再入院率分别为180例(6.57%)与24204例(5.01%),差异无统计学意义(p=0.453)。
  • 肝硬化与更高的肝性脑病和急性心衰发生率相关,且住院时间更长、费用更高、非居家出院更常见。
  • 肝硬化患者中,Roux-en-Y胃旁路术再入院风险高于袖状胃切除术(OR 1.63,95%CI 1.18-2.25,p=0.003)。
  • 肝硬化患者中,十二指肠转位术再入院风险高于袖状胃切除术(OR 3.54,95%CI 1.42-8.85,p=0.007)。

临床怎么用

  • 代偿性肝硬化并非代谢与减重手术的绝对禁忌,术前应评估肝硬化代偿状态。
  • 肝硬化患者术后需关注肝性脑病和急性心衰风险,并预计更长住院和更高费用。
  • 肝硬化患者选择术式时,袖状胃切除术可能较Roux-en-Y胃旁路术和十二指肠转位术再入院风险更低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is still a lack of sufficient data regarding the trend of cirrhosis and its impact on the perioperative and postoperative outcomes, and healthcare resource utilization in patients who underwent metabolic and bariatric surgery (MBS). Therefore, our study aimed to examine the impact of cirrhosis on MBS outcomes. METHODS: The current study used the Nationwide Readmissions Database (NRD) 2016-2020. Patients who underwent MBS were divided into cirrhosis and non-cirrhosis groups. Patients younger than 18 years, those with a history of upper gastrointestinal malignancy, and patients with decompensated cirrhosis (portal hypertension, ascites, or varices) and individuals with a previous history of MBS were excluded. RESULTS: The cirrhosis and non-cirrhosis groups consisted of 3064 and 538,329 patients, respectively. There was no significant change in the cirrhosis trend in patients who underwent MBS from 2016 to 2020. Cirrhosis was not associated with higher rates of in-hospital mortality (< 11 (< 0.36%) vs 99 (0.02%), p = 0.140), 90-day readmission (180 (6.57%) vs 24,204 (5.01%), p = 0.453), or most major complications. Although the overall incidence was low, cirrhosis was linked to higher rates of hepatic encephalopathy and acute heart failure. Patients with cirrhosis also had longer hospital stays, higher costs, and were more likely to have a non-home discharge. Among patients with cirrhosis, Roux-en-Y gastric bypass (OR 1.63, 95% CI 1.18-2.25, p = 0.003) and duodenal switch (OR 3.54, 95% CI 1.42-8.85, p = 0.007) were associated with a higher readmission rates compared to sleeve gastrectomy. CONCLUSION: These results may indicate the safety of MBS in patients with compensated cirrhosis and obesity.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Esparham A, Phillippe S, Khorgami Z, et al. National trend and impact of compensated cirrhosis in patients who underwent metabolic and bariatric surgery: a Nationwide Readmissions Database study. Surg Endosc. 2026. PMID: 41514130. doi:10.1007/s00464-025-12497-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。